Present and Possible Therapies for Age-Related Macular Degeneration

Present and Possible Therapies for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly population worldwide and is defined as a chronic, progressive disorder characterized by changes occurring within the macula reflective of the ageing process. At present, the prevalence of AMD is currently ris...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ISRN ophthalmology 2014-04, Vol.2014, p.608390-7
Hauptverfasser: Khan, Muhammad, Agarwal, Ketan, Loutfi, Mohamed, Kamal, Ahmed
Format: Artikel
Sprache:eng
Schlagworte:
Review
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7
container_issue
container_start_page 608390
container_title ISRN ophthalmology
container_volume 2014
creator Khan, Muhammad
Agarwal, Ketan
Loutfi, Mohamed
Kamal, Ahmed
description Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly population worldwide and is defined as a chronic, progressive disorder characterized by changes occurring within the macula reflective of the ageing process. At present, the prevalence of AMD is currently rising and is estimated to increase by a third by 2020. Although our understanding of the several components underpinning the pathogenesis of this condition has increased significantly, the treatment options for this condition remain substantially limited. In this review, we outline the existing arsenal of therapies available for AMD and discuss the additional role of further novel therapies currently under investigation for this debilitating disease.
doi_str_mv 10.1155/2014/608390
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4009180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25097787</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2610-b267c474dbeab2337fd9a2a73f1384a08c18580393d6400b7870cd41f6ef62213</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoVmpP3mXPytpJspuPi1DqJ1QsUs8hu5ltI9vdkm0V_70p1aIXc0lgnjwz8xJyRuGK0jwfMqDZUIDiGg7ICQMNaS60ONy_leqRQde9QTwSmNLsmPRYDlpKJU_IeBqww2ad2MYl07brfFFjMltgsCuPXVK1IRnNMX3B2q7RJU-23NQ2JDc4xyZCa982p-SosnWHg--7T17vbmfjh3TyfP84Hk3SkgkKacGELDOZuQJtwTiXldOWWckrylVmQZVU5Qq45k5kAEWcD0qX0UpgJRijvE-ud97VpliiK-PYwdZmFfzShk_TWm_-Vhq_MPP23USbptHcJ5c7QRnipgGr_V8KZhun2cZpdnFG-vx3uz37E14ELnbAwjfOfvh_bV8w_3wE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Present and Possible Therapies for Age-Related Macular Degeneration</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Khan, Muhammad ; Agarwal, Ketan ; Loutfi, Mohamed ; Kamal, Ahmed</creator><contributor>Kakehashi, A. ; Bashshur, Z. ; Pierro, L.</contributor><creatorcontrib>Khan, Muhammad ; Agarwal, Ketan ; Loutfi, Mohamed ; Kamal, Ahmed ; Kakehashi, A. ; Bashshur, Z. ; Pierro, L.</creatorcontrib><description>Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly population worldwide and is defined as a chronic, progressive disorder characterized by changes occurring within the macula reflective of the ageing process. At present, the prevalence of AMD is currently rising and is estimated to increase by a third by 2020. Although our understanding of the several components underpinning the pathogenesis of this condition has increased significantly, the treatment options for this condition remain substantially limited. In this review, we outline the existing arsenal of therapies available for AMD and discuss the additional role of further novel therapies currently under investigation for this debilitating disease.</description><identifier>ISSN: 2090-5688</identifier><identifier>ISSN: 2090-5696</identifier><identifier>EISSN: 2090-5696</identifier><identifier>DOI: 10.1155/2014/608390</identifier><identifier>PMID: 25097787</identifier><language>eng</language><publisher>Egypt: Hindawi Publishing Corporation</publisher><subject>Review</subject><ispartof>ISRN ophthalmology, 2014-04, Vol.2014, p.608390-7</ispartof><rights>Copyright © 2014 Muhammad Khan et al.</rights><rights>Copyright © 2014 Muhammad Khan et al. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2610-b267c474dbeab2337fd9a2a73f1384a08c18580393d6400b7870cd41f6ef62213</citedby><cites>FETCH-LOGICAL-c2610-b267c474dbeab2337fd9a2a73f1384a08c18580393d6400b7870cd41f6ef62213</cites><orcidid>0000-0001-8807-2970 ; 0000-0002-6054-0952 ; 0000-0002-1430-0317</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009180/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009180/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25097787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kakehashi, A.</contributor><contributor>Bashshur, Z.</contributor><contributor>Pierro, L.</contributor><creatorcontrib>Khan, Muhammad</creatorcontrib><creatorcontrib>Agarwal, Ketan</creatorcontrib><creatorcontrib>Loutfi, Mohamed</creatorcontrib><creatorcontrib>Kamal, Ahmed</creatorcontrib><title>Present and Possible Therapies for Age-Related Macular Degeneration</title><title>ISRN ophthalmology</title><addtitle>ISRN Ophthalmol</addtitle><description>Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly population worldwide and is defined as a chronic, progressive disorder characterized by changes occurring within the macula reflective of the ageing process. At present, the prevalence of AMD is currently rising and is estimated to increase by a third by 2020. Although our understanding of the several components underpinning the pathogenesis of this condition has increased significantly, the treatment options for this condition remain substantially limited. In this review, we outline the existing arsenal of therapies available for AMD and discuss the additional role of further novel therapies currently under investigation for this debilitating disease.</description><subject>Review</subject><issn>2090-5688</issn><issn>2090-5696</issn><issn>2090-5696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><recordid>eNp9kE1LAzEQhoMoVmpP3mXPytpJspuPi1DqJ1QsUs8hu5ltI9vdkm0V_70p1aIXc0lgnjwz8xJyRuGK0jwfMqDZUIDiGg7ICQMNaS60ONy_leqRQde9QTwSmNLsmPRYDlpKJU_IeBqww2ad2MYl07brfFFjMltgsCuPXVK1IRnNMX3B2q7RJU-23NQ2JDc4xyZCa982p-SosnWHg--7T17vbmfjh3TyfP84Hk3SkgkKacGELDOZuQJtwTiXldOWWckrylVmQZVU5Qq45k5kAEWcD0qX0UpgJRijvE-ud97VpliiK-PYwdZmFfzShk_TWm_-Vhq_MPP23USbptHcJ5c7QRnipgGr_V8KZhun2cZpdnFG-vx3uz37E14ELnbAwjfOfvh_bV8w_3wE</recordid><startdate>20140416</startdate><enddate>20140416</enddate><creator>Khan, Muhammad</creator><creator>Agarwal, Ketan</creator><creator>Loutfi, Mohamed</creator><creator>Kamal, Ahmed</creator><general>Hindawi Publishing Corporation</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8807-2970</orcidid><orcidid>https://orcid.org/0000-0002-6054-0952</orcidid><orcidid>https://orcid.org/0000-0002-1430-0317</orcidid></search><sort><creationdate>20140416</creationdate><title>Present and Possible Therapies for Age-Related Macular Degeneration</title><author>Khan, Muhammad ; Agarwal, Ketan ; Loutfi, Mohamed ; Kamal, Ahmed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2610-b267c474dbeab2337fd9a2a73f1384a08c18580393d6400b7870cd41f6ef62213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Muhammad</creatorcontrib><creatorcontrib>Agarwal, Ketan</creatorcontrib><creatorcontrib>Loutfi, Mohamed</creatorcontrib><creatorcontrib>Kamal, Ahmed</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ISRN ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khan, Muhammad</au><au>Agarwal, Ketan</au><au>Loutfi, Mohamed</au><au>Kamal, Ahmed</au><au>Kakehashi, A.</au><au>Bashshur, Z.</au><au>Pierro, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Present and Possible Therapies for Age-Related Macular Degeneration</atitle><jtitle>ISRN ophthalmology</jtitle><addtitle>ISRN Ophthalmol</addtitle><date>2014-04-16</date><risdate>2014</risdate><volume>2014</volume><spage>608390</spage><epage>7</epage><pages>608390-7</pages><issn>2090-5688</issn><issn>2090-5696</issn><eissn>2090-5696</eissn><abstract>Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly population worldwide and is defined as a chronic, progressive disorder characterized by changes occurring within the macula reflective of the ageing process. At present, the prevalence of AMD is currently rising and is estimated to increase by a third by 2020. Although our understanding of the several components underpinning the pathogenesis of this condition has increased significantly, the treatment options for this condition remain substantially limited. In this review, we outline the existing arsenal of therapies available for AMD and discuss the additional role of further novel therapies currently under investigation for this debilitating disease.</abstract><cop>Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>25097787</pmid><doi>10.1155/2014/608390</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-8807-2970</orcidid><orcidid>https://orcid.org/0000-0002-6054-0952</orcidid><orcidid>https://orcid.org/0000-0002-1430-0317</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-5688
ispartof ISRN ophthalmology, 2014-04, Vol.2014, p.608390-7
issn 2090-5688
2090-5696
2090-5696
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4009180
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central
subjects Review
title Present and Possible Therapies for Age-Related Macular Degeneration
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A42%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Present%20and%20Possible%20Therapies%20for%20Age-Related%20Macular%20Degeneration&rft.jtitle=ISRN%20ophthalmology&rft.au=Khan,%20Muhammad&rft.date=2014-04-16&rft.volume=2014&rft.spage=608390&rft.epage=7&rft.pages=608390-7&rft.issn=2090-5688&rft.eissn=2090-5696&rft_id=info:doi/10.1155/2014/608390&rft_dat=%3Cpubmed_cross%3E25097787%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25097787&rfr_iscdi=true